Harrow (HROW) Cost of Revenue (2014 - 2026)
Harrow's (HROW) quarterly Cost of Revenue came in at $17.2 million in Q1 2026, up 10.53% year-on-year from $15.5 million in Q1 2025, and down 7.09% quarter-over-quarter from $18.5 million in Q4 2025.
Harrow (HROW) Cost of Revenue (2014 - 2026) Analysis & Trends
Harrow's Cost of Revenue history runs 13 years deep, the most recent figure standing at $17.2 million for Q1 2026.
- On a quarterly basis, Cost of Revenue rose 10.53% year-over-year to $17.2 million in Q1 2026; TTM through Mar 2026 was $69.6 million, a 28.32% increase from a year earlier, with the FY2025 full-year figure at $67.9 million, up 37.95% from the prior year.
- Cost of Revenue retreated to $17.2 million in Q1 2026 per HROW's latest filing, from $18.5 million in the prior quarter.
- Across five years, Cost of Revenue topped out at $18.5 million in Q4 2025 and bottomed at $6.0 million in Q1 2022.
- The 5-year median for Cost of Revenue is $11.3 million (2023), against an average of $11.7 million.
- Across the five-year window, Cost of Revenue surged 83.33% in 2023 and increased 10.53% in 2026, its largest moves.
- Year by year, Cost of Revenue stood at $6.2 million in 2022, then jumped by 83.33% to $11.3 million in 2023, then advanced by 25.07% to $14.1 million in 2024, then soared by 30.65% to $18.5 million in 2025, then declined by 7.09% to $17.2 million in 2026.
- Per Business Quant, the three latest HROW Cost of Revenue figures stand at $17.2 million (Q1 2026), $18.5 million (Q4 2025), and $17.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 2.01 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 641.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 2.59 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 133.40 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 2.36 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 13.80 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 586.00 Mn |
| 10 | Harrow | 1.41 Bn | 1.32 Bn | 27.05 Mn | 17.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.16 Mn |
| Mar 31, 2026 | 17.16 Mn |
| Dec 31, 2025 | 18.47 Mn |
| Dec 31, 2025 | 18.47 Mn |
| Sep 30, 2025 | 17.71 Mn |
| Sep 30, 2025 | 17.71 Mn |
| Jun 30, 2025 | 16.23 Mn |
| Jun 30, 2025 | 16.23 Mn |
| Mar 31, 2025 | 15.52 Mn |
| Mar 31, 2025 | 15.52 Mn |
| Dec 31, 2024 | 14.14 Mn |
| Dec 31, 2024 | 14.14 Mn |
| Sep 30, 2024 | 12.02 Mn |
| Sep 30, 2024 | 12.02 Mn |
| Jun 30, 2024 | 12.54 Mn |
| Jun 30, 2024 | 12.54 Mn |
| Mar 31, 2024 | 10.55 Mn |
| Mar 31, 2024 | 10.55 Mn |
| Dec 31, 2023 | 11.30 Mn |
| Dec 31, 2023 | 11.30 Mn |